Personal tools

CL:0000135: Difference between revisions

From FANTOM5_SSTAR

Jump to: navigation, search
No edit summary
No edit summary
 
(2 intermediate revisions by the same user not shown)
Line 1: Line 1:
{{CL
{{CL
|id=CL:0000135
|alt_id=
|name=fibrocyte
|namespace=cell
|def="An inactive fibroblast; cytoplasm is sparse, endoplasmic reticulum is scanty with flattened nucleus. Term used by some histologists; when fibroblasts become relatively inactive in fiber formation. However, this cell has the potential for fibrogenesis in quiescent connective tissue of the adult, as well as during development, other histologists prefer to use the term fibroblast in all circumstances. These cells represent ~0.5% of peripheral blood leukocytes." [GOC:dsd, GOC:tfm, ISBN:0412046911, ISBN:0517223651, PMID:11641248, PMID:15010326, PMID:17607298, PMID:18222966, PMID:8790603, PMID:9551999]
|xref=FMA:63879
|is_a=CL:0000499
|synonym=
|comment=Cultured human fibrocytes are MHCI-positive, MHCII-positive, CD1a-negative, CD3-negative, CD4-negative, CD8-negative, CD10-negative, CD11b-positive, CD13-positive, CD14-negative, CD16-negative, CD18-positive, CD19-negative, CD25-negative, CD29-positive, CD32-positive, CD33-negative, CD34-positive, CD38-negative, CD40-positive, CD44-negative, CD45RO-positive, CD49a-positive, CD49b-positive, CD49c-negative, CD49d-negative, CD49e-positive, CD49f-negative, CD56-negative, CD58-positive, CD61-positive, CD64-positive, CD70-negative, CD71-positive, CD80-positive, CD83-negative, CD86-positive, CD103-negative, CD105-positive, CD181-positive, CD182-negative, CD183-positive, CD184-positive, CD185-negative, CD186-negative, CD191-positive, CD192-negative, CD193-positive, CD194-positive, CD195-positive, CD196-negative, CD197-positive, CD199-positive, desmin-negative, F4/80-positive, Gr1-positive, LSP-1-positive, MHCI-positive, MHCII-positive, alpha-SMA-negative, TCRab-negative, TCRgd-negative, and vimentin-positive.  Fibrocytes are also capable of secreting angiogenin, bFGF, CCL2, CCL3, CCL4, CCL8, CXCL1, type I collagen, type III collagen, CTGF, fibronectin, GM-CSF, IL-1a, IL-6, IL-8, IL-10, M-CSF, MMP-9, PDGF-A, TGF-alpha, TGF-beta1, TNF-alpha, VEGF-A, and type I collagen.
|comment=Cultured human fibrocytes are MHCI-positive, MHCII-positive, CD1a-negative, CD3-negative, CD4-negative, CD8-negative, CD10-negative, CD11b-positive, CD13-positive, CD14-negative, CD16-negative, CD18-positive, CD19-negative, CD25-negative, CD29-positive, CD32-positive, CD33-negative, CD34-positive, CD38-negative, CD40-positive, CD44-negative, CD45RO-positive, CD49a-positive, CD49b-positive, CD49c-negative, CD49d-negative, CD49e-positive, CD49f-negative, CD56-negative, CD58-positive, CD61-positive, CD64-positive, CD70-negative, CD71-positive, CD80-positive, CD83-negative, CD86-positive, CD103-negative, CD105-positive, CD181-positive, CD182-negative, CD183-positive, CD184-positive, CD185-negative, CD186-negative, CD191-positive, CD192-negative, CD193-positive, CD194-positive, CD195-positive, CD196-negative, CD197-positive, CD199-positive, desmin-negative, F4/80-positive, Gr1-positive, LSP-1-positive, MHCI-positive, MHCII-positive, alpha-SMA-negative, TCRab-negative, TCRgd-negative, and vimentin-positive.  Fibrocytes are also capable of secreting angiogenin, bFGF, CCL2, CCL3, CCL4, CCL8, CXCL1, type I collagen, type III collagen, CTGF, fibronectin, GM-CSF, IL-1a, IL-6, IL-8, IL-10, M-CSF, MMP-9, PDGF-A, TGF-alpha, TGF-beta1, TNF-alpha, VEGF-A, and type I collagen.
|alt_id=
|disjoint_from=
|union_of=
|created_by=
|created_by=
|obo_creation_date=
|def="An inactive fibroblast; cytoplasm is sparse, endoplasmic reticulum is scanty with flattened nucleus. Term used by some histologists; when fibroblasts become relatively inactive in fiber formation. However, this cell has the potential for fibrogenesis in quiescent connective tissue of the adult, as well as during development, other histologists prefer to use the term fibroblast in all circumstances. These cells represent ~0.5% of peripheral blood leukocytes." [GOC:dsd, GOC:tfm, ISBN:0412046911, ISBN:0517223651, PMID:11641248, PMID:15010326, PMID:17607298, PMID:18222966, PMID:8790603, PMID:9551999]
|subset=
|derives_from=
|derives_from=
|develops_from=
|develops_from=CL:0000057
|disjoint_from=
|has_quality=
|has_quality=
|id=CL:0000135
|is_a=CL:0000499
|is_obsolete=
|located_in=
|located_in=
|name=fibrocyte
|namespace=FANTOM
|obo_creation_date=
|part_of=
|part_of=
|preceded_by=
|property_value=IAO:0000412 http://purl.obolibrary.org/obo/cl.owl
|property_value=IAO:0000412 http://purl.obolibrary.org/obo/cl.owl
|is_obsolete=
|subset=
|preceded_by=
|synonym=
|union_of=
|xref=FMA:63879
}}
}}

Latest revision as of 16:30, 12 September 2014

Name:fibrocyte
Namespace:FANTOM
Definition:"An inactive fibroblast; cytoplasm is sparse, endoplasmic reticulum is scanty with flattened nucleus. Term used by some histologists; when fibroblasts become relatively inactive in fiber formation. However, this cell has the potential for fibrogenesis in quiescent connective tissue of the adult, as well as during development, other histologists prefer to use the term fibroblast in all circumstances. These cells represent ~0.5% of peripheral blood leukocytes." [GOC:dsd, GOC:tfm, ISBN:0412046911, ISBN:0517223651, PMID:11641248, PMID:15010326, PMID:17607298, PMID:18222966, PMID:8790603, PMID:9551999]
Xrefs:
links:
FMA:63879
Comments:Cultured human fibrocytes are MHCI-positive, MHCII-positive, CD1a-negative, CD3-negative, CD4-negative, CD8-negative, CD10-negative, CD11b-positive, CD13-positive, CD14-negative, CD16-negative, CD18-positive, CD19-negative, CD25-negative, CD29-positive, CD32-positive, CD33-negative, CD34-positive, CD38-negative, CD40-positive, CD44-negative, CD45RO-positive, CD49a-positive, CD49b-positive, CD49c-negative, CD49d-negative, CD49e-positive, CD49f-negative, CD56-negative, CD58-positive, CD61-positive, CD64-positive, CD70-negative, CD71-positive, CD80-positive, CD83-negative, CD86-positive, CD103-negative, CD105-positive, CD181-positive, CD182-negative, CD183-positive, CD184-positive, CD185-negative, CD186-negative, CD191-positive, CD192-negative, CD193-positive, CD194-positive, CD195-positive, CD196-negative, CD197-positive, CD199-positive, desmin-negative, F4/80-positive, Gr1-positive, LSP-1-positive, MHCI-positive, MHCII-positive, alpha-SMA-negative, TCRab-negative, TCRgd-negative, and vimentin-positive. Fibrocytes are also capable of secreting angiogenin, bFGF, CCL2, CCL3, CCL4, CCL8, CXCL1, type I collagen, type III collagen, CTGF, fibronectin, GM-CSF, IL-1a, IL-6, IL-8, IL-10, M-CSF, MMP-9, PDGF-A, TGF-alpha, TGF-beta1, TNF-alpha, VEGF-A, and type I collagen.


Ontology association <br>Each term has an is_a parent in the Cell ontology, which has a linkage to an another entity and FANTOM5 samples.Libraries were grouped into mutually exclusive facets according to the FANTOM5 sample ontology mapping to Cell ontologies.<br><br>link to ontology dataset<br>data

Parents

is_a:CL:0000499(stromal cell)
develops_from:CL:0000057(fibroblast)



Children


is a:CL:0000388 (tendon cell)

Ontology Tree: Loaded from BioPortal

Ontorolgy tree(Small window open)


FF samples<br>It includes FANTOM5 samples that overlay the Cell ontology.

Human (Homo sapiens)

Mouse (Mus musculus)


Enrichment analysis: top 100 FFCP enriched with this ontology termTOP 100 FANTOM5 Cage Peaks enriched with CL:0000135 (fibrocyte), sorted by p-values <br>Analyst: Hideya Kawaji<br><br>link to source dataset <br>human : data <br>mouse : data

P-valueFFCPShort description
9.74e-88FFCP PHASE1:Hg19::chr1:203150041..203150049,-#_e06a7acb0cd63bbf5222a6fb13341051p@chr1:203150041..203150049, -
9.74e-88FFCP PHASE2:Hg19::chr1:203150041..203150049,-#_e06a7acb0cd63bbf5222a6fb13341051p@chr1:203150041..203150049, -
2.75e-74FFCP PHASE2:Hg19::chr5:79375755..79375801,+#_28734fc3b1b5b270da7b556e88db8734p@chr5:79375755..79375801, +
2.75e-74FFCP PHASE1:Hg19::chr5:79375755..79375801,+#_28734fc3b1b5b270da7b556e88db8734p@chr5:79375755..79375801, +
2.39e-66FFCP PHASE2:Hg19::chr4:4396380..4396381,-#_665dc4e2e6e6b85f5e2d0f36a2cb8660p@chr4:4396380..4396381, -
2.39e-66FFCP PHASE1:Hg19::chr7:43016260..43016261,+#_665dc4e2e6e6b85f5e2d0f36a2cb8660p@chr7:43016260..43016261, +
2.39e-66FFCP PHASE1:Hg19::chr11:27541356..27541360,+#_665dc4e2e6e6b85f5e2d0f36a2cb8660p@chr11:27541356..27541360, +
2.39e-66FFCP PHASE1:Hg19::chr4:4396380..4396381,-#_665dc4e2e6e6b85f5e2d0f36a2cb8660p@chr4:4396380..4396381, -
2.39e-66FFCP PHASE2:Hg19::chr11:27541356..27541360,+#_665dc4e2e6e6b85f5e2d0f36a2cb8660p@chr11:27541356..27541360, +
2.39e-66FFCP PHASE2:Hg19::chr7:43016260..43016261,+#_665dc4e2e6e6b85f5e2d0f36a2cb8660p@chr7:43016260..43016261, +
2.4e-66FFCP PHASE1:Hg19::chr1:203150031..203150040,-#_51a70970a57fecc913b287e36859a8efp@chr1:203150031..203150040, -
2.4e-66FFCP PHASE2:Hg19::chr1:203150031..203150040,-#_51a70970a57fecc913b287e36859a8efp@chr1:203150031..203150040, -
2.41e-66FFCP PHASE2:Hg19::chr8:120608233..120608244,-#_15bf093b24156e8aabcdb9ea1fe0085bp@chr8:120608233..120608244, -
2.41e-66FFCP PHASE1:Hg19::chr8:120608233..120608244,-#_15bf093b24156e8aabcdb9ea1fe0085bp@chr8:120608233..120608244, -
1.22e-59FFCP PHASE2:Hg19::chr7:80373118..80373135,-#_165e9ab4aece570f8351f3b159866b99p21@SEMA3C
1.22e-59FFCP PHASE1:Hg19::chr7:80373118..80373135,-#_165e9ab4aece570f8351f3b159866b99p21@SEMA3C
3.13e-54FFCP PHASE2:Hg19::chr8:57353995..57354004,-#_1e48411084d10453adcb20dd7b30569ep@chr8:57353995..57354004, -
3.13e-54FFCP PHASE1:Hg19::chr8:57353995..57354004,-#_1e48411084d10453adcb20dd7b30569ep@chr8:57353995..57354004, -
9.77e-45FFCP PHASE2:Hg19::chr6:159660765..159660776,+#_8107df191602c074a7a223d8d5f9577fp@chr6:159660765..159660776, +
9.77e-45FFCP PHASE1:Hg19::chr6:159660765..159660776,+#_8107df191602c074a7a223d8d5f9577fp@chr6:159660765..159660776, +
6.64e-41FFCP PHASE1:Hg19::chr1:56962127..56962135,-#_c27a6cb2b45bbbafdb4fc44463341901p@chr1:56962127..56962135, -
6.64e-41FFCP PHASE2:Hg19::chr1:56962127..56962135,-#_c27a6cb2b45bbbafdb4fc44463341901p@chr1:56962127..56962135, -
2.93e-40FFCP PHASE2:Hg19::chr4:26492048..26492059,-#_33aa53b972a57459a684cb97d792254bp3@CCKAR
2.93e-40FFCP PHASE1:Hg19::chr4:26492048..26492059,-#_33aa53b972a57459a684cb97d792254bp3@CCKAR
9.77e-40FFCP PHASE2:Hg19::chr8:57354119..57354137,+#_a0de3e82e017f9765af8ab177f137a8cp@chr8:57354119..57354137, +
9.77e-40FFCP PHASE1:Hg19::chr8:57354119..57354137,+#_a0de3e82e017f9765af8ab177f137a8cp@chr8:57354119..57354137, +
1.46e-39FFCP PHASE2:Hg19::chr19:18895742..18895757,-#_7e5a2c0dde3299cecd01c70c32023f34p@chr19:18895742..18895757, -
1.46e-39FFCP PHASE1:Hg19::chr19:18895742..18895757,-#_7e5a2c0dde3299cecd01c70c32023f34p@chr19:18895742..18895757, -
6.91e-39FFCP PHASE2:Hg19::chr7:15725581..15725587,-#_01295efa77ac33427f758742133c75b7p13@MEOX2
6.91e-39FFCP PHASE1:Hg19::chr7:15725581..15725587,-#_01295efa77ac33427f758742133c75b7p13@MEOX2
8.37e-39FFCP PHASE2:Hg19::chr1:203149809..203149816,-#_8c640c7e88637814c829febc0eb97de6p@chr1:203149809..203149816, -
8.37e-39FFCP PHASE1:Hg19::chr1:203149809..203149816,-#_8c640c7e88637814c829febc0eb97de6p@chr1:203149809..203149816, -
1.01e-38FFCP PHASE2:Hg19::chr1:203152872..203152879,-#_c7171fce1f8d58f7a6f95eb01600c9f2p@chr1:203152872..203152879, -
1.01e-38FFCP PHASE1:Hg19::chr1:203152872..203152879,-#_c7171fce1f8d58f7a6f95eb01600c9f2p@chr1:203152872..203152879, -
3.19e-38FFCP PHASE2:Hg19::chr18:61495529..61495546,+#_dfa0d150b2477930e28b05edee8bb58cp@chr18:61495529..61495546, +
3.19e-38FFCP PHASE1:Hg19::chr18:61495529..61495546,+#_dfa0d150b2477930e28b05edee8bb58cp@chr18:61495529..61495546, +
8.41e-38FFCP PHASE2:Hg19::chr8:110346720..110346722,-#_c77f4b8c191465439e3d3cee19e55ff1p5@NUDCD1
8.41e-38FFCP PHASE1:Hg19::chr8:110346720..110346722,-#_c77f4b8c191465439e3d3cee19e55ff1p5@NUDCD1
2.95e-37FFCP PHASE2:Hg19::chr10:28033776..28033788,+#_9a84536e4b483af26b0355fb8018c7a3p1@ENST00000419777
2.95e-37FFCP PHASE1:Hg19::chr10:28033776..28033788,+#_9a84536e4b483af26b0355fb8018c7a3p1@ENST00000419777
1.39e-34FFCP PHASE1:Hg19::chr1:203148394..203148401,-#_94a07ddf98079bf37279dffe68279745p10@CHI3L1
1.39e-34FFCP PHASE2:Hg19::chr1:203148394..203148401,-#_94a07ddf98079bf37279dffe68279745p10@CHI3L1
2.19e-34FFCP PHASE2:Hg19::chr12:91502776..91502785,-#_d88bc37b54143983707de36857c134ddp15@LUM
2.19e-34FFCP PHASE2:Hg19::chr7:87906696..87906704,-#_d88bc37b54143983707de36857c134ddp@chr7:87906696..87906704, -
2.19e-34FFCP PHASE1:Hg19::chr12:91502776..91502785,-#_d88bc37b54143983707de36857c134ddp15@LUM
2.19e-34FFCP PHASE1:Hg19::chr7:87906696..87906704,-#_d88bc37b54143983707de36857c134ddp@chr7:87906696..87906704, -
4.27e-34FFCP PHASE2:Hg19::chr1:203153416..203153419,-#_d69db016f4dc7278474a3dc9576c9dc4p@chr1:203153416..203153419, -
4.27e-34FFCP PHASE1:Hg19::chr1:203153416..203153419,-#_d69db016f4dc7278474a3dc9576c9dc4p@chr1:203153416..203153419, -
5.96e-34FFCP PHASE1:Hg19::chr1:110471879..110471901,+#_37d0d1b252e63de400a89cfb77849fe3p@chr1:110471879..110471901, +
5.96e-34FFCP PHASE2:Hg19::chr10:127350469..127350475,-#_37d0d1b252e63de400a89cfb77849fe3p@chr10:127350469..127350475, -
5.96e-34FFCP PHASE2:Hg19::chr1:110471879..110471901,+#_37d0d1b252e63de400a89cfb77849fe3p@chr1:110471879..110471901, +
5.96e-34FFCP PHASE1:Hg19::chr10:127350469..127350475,-#_37d0d1b252e63de400a89cfb77849fe3p@chr10:127350469..127350475, -
8.46e-34FFCP PHASE1:Hg19::chr1:56320708..56320728,-#_05743d96fa539cd64c11be068242ab1ep@chr1:56320708..56320728, -
8.46e-34FFCP PHASE2:Hg19::chr1:56320708..56320728,-#_05743d96fa539cd64c11be068242ab1ep@chr1:56320708..56320728, -
9.1e-34FFCP PHASE1:Hg19::chr8:57354463..57354473,+#_61ff63221f26967096fd83b845cc5d13p@chr8:57354463..57354473, +
9.1e-34FFCP PHASE2:Hg19::chr8:57354463..57354473,+#_61ff63221f26967096fd83b845cc5d13p@chr8:57354463..57354473, +
2.31e-33FFCP PHASE2:Hg19::chr18:43418712..43418734,+#_ae3ce033d9f62517babfe153cc8d388bp7@SIGLEC15
2.31e-33FFCP PHASE1:Hg19::chr18:43418712..43418734,+#_ae3ce033d9f62517babfe153cc8d388bp7@SIGLEC15
7.76e-32FFCP PHASE1:Hg19::chr19:18899448..18899459,-#_baaba1921ace7794c2da1d9719c06154p@chr19:18899448..18899459, -
7.76e-32FFCP PHASE2:Hg19::chr19:18899448..18899459,-#_baaba1921ace7794c2da1d9719c06154p@chr19:18899448..18899459, -
1.32e-31FFCP PHASE1:Hg19::chr3:100494130..100494141,-#_25968184ba00a9a15287ce0326bdaeddp@chr3:100494130..100494141, -
1.32e-31FFCP PHASE2:Hg19::chr3:100494130..100494141,-#_25968184ba00a9a15287ce0326bdaeddp@chr3:100494130..100494141, -
9.03e-31FFCP PHASE1:Hg19::chr19:18900031..18900054,+#_f486607db526b1f2df2c3f9a0403069bp@chr19:18900031..18900054, +
9.03e-31FFCP PHASE2:Hg19::chr19:18900031..18900054,+#_f486607db526b1f2df2c3f9a0403069bp@chr19:18900031..18900054, +
1.09e-30FFCP PHASE1:Hg19::chr1:161969956..161969963,-#_c41c1de2130e69e65674d4749d7f86cdp@chr1:161969956..161969963, -
1.09e-30FFCP PHASE2:Hg19::chr1:161969956..161969963,-#_c41c1de2130e69e65674d4749d7f86cdp@chr1:161969956..161969963, -
2.48e-30FFCP PHASE1:Hg19::chr19:18896512..18896527,-#_27d431c7a033078aeac049e207bbda51p@chr19:18896512..18896527, -
2.48e-30FFCP PHASE2:Hg19::chr19:18896512..18896527,-#_27d431c7a033078aeac049e207bbda51p@chr19:18896512..18896527, -
2.67e-30FFCP PHASE2:Hg19::chr5:79351765..79351792,+#_7b079bc737ca5f16d58ee0d6be814f98p@chr5:79351765..79351792, +
2.67e-30FFCP PHASE1:Hg19::chr5:79351765..79351792,+#_7b079bc737ca5f16d58ee0d6be814f98p@chr5:79351765..79351792, +
5.0e-30FFCP PHASE2:Hg19::chr20:48140767..48140776,-#_9ce1e8d123ddb6fa178894ea559fb6cbp@chr20:48140767..48140776, -
5.0e-30FFCP PHASE1:Hg19::chr20:48140767..48140776,-#_9ce1e8d123ddb6fa178894ea559fb6cbp@chr20:48140767..48140776, -
2.91e-29FFCP PHASE2:Hg19::chr19:18895812..18895830,-#_557ac451c2cc0679d98d012b60489e76p@chr19:18895812..18895830, -
2.91e-29FFCP PHASE1:Hg19::chr19:18895812..18895830,-#_557ac451c2cc0679d98d012b60489e76p@chr19:18895812..18895830, -
5.18e-29FFCP PHASE2:Hg19::chr15:81243109..81243120,+#_0cf4e3fb5af8bd10cecf90bc82cfd870p@chr15:81243109..81243120, +
5.18e-29FFCP PHASE1:Hg19::chr15:81243109..81243120,+#_0cf4e3fb5af8bd10cecf90bc82cfd870p@chr15:81243109..81243120, +
1.11e-28FFCP PHASE2:Hg19::chr19:18896642..18896656,-#_cc43106f561a6abec9cc953f26a7d468p@chr19:18896642..18896656, -
1.11e-28FFCP PHASE1:Hg19::chr19:18896642..18896656,-#_cc43106f561a6abec9cc953f26a7d468p@chr19:18896642..18896656, -
1.42e-28FFCP PHASE1:Hg19::chr1:56977818..56977827,-#_85df61fefd09601e105063a1d68505e3p@chr1:56977818..56977827, -
1.42e-28FFCP PHASE2:Hg19::chr1:56977818..56977827,-#_85df61fefd09601e105063a1d68505e3p@chr1:56977818..56977827, -
2.06e-28FFCP PHASE1:Hg19::chr17:38613300..38613311,-#_4ae2960b9f7532e05b509a58986bb457p@chr17:38613300..38613311, -
2.06e-28FFCP PHASE2:Hg19::chr17:38613300..38613311,-#_4ae2960b9f7532e05b509a58986bb457p@chr17:38613300..38613311, -
3.59e-28FFCP PHASE1:Hg19::chr3:69154031..69154043,+#_64ac6d6078bb57182a1ee7b42f156f06p@chr3:69154031..69154043, +
3.59e-28FFCP PHASE2:Hg19::chr1:203148495..203148505,-#_64ac6d6078bb57182a1ee7b42f156f06p13@CHI3L1
3.59e-28FFCP PHASE2:Hg19::chr3:69154031..69154043,+#_64ac6d6078bb57182a1ee7b42f156f06p@chr3:69154031..69154043, +
3.59e-28FFCP PHASE1:Hg19::chr1:203148495..203148505,-#_64ac6d6078bb57182a1ee7b42f156f06p13@CHI3L1
6.24e-28FFCP PHASE2:Hg19::chr8:57354275..57354292,-#_c80acbc11fc4f2e8acabecaf01a34ff4p@chr8:57354275..57354292, -
6.24e-28FFCP PHASE1:Hg19::chr8:57354275..57354292,-#_c80acbc11fc4f2e8acabecaf01a34ff4p@chr8:57354275..57354292, -
9.35e-28FFCP PHASE1:Hg19::chr4:26491909..26491918,-#_ca559946b244d13a3c946a7465872ffcp2@CCKAR
9.35e-28FFCP PHASE2:Hg19::chr4:26491909..26491918,-#_ca559946b244d13a3c946a7465872ffcp2@CCKAR
1.19e-27FFCP PHASE2:Hg19::chr3:86992689..86992700,-#_eda155454f382595339e22b3dfa39030p@chr3:86992689..86992700, -
1.19e-27FFCP PHASE1:Hg19::chr3:86992689..86992700,-#_eda155454f382595339e22b3dfa39030p@chr3:86992689..86992700, -
1.39e-27FFCP PHASE2:Hg19::chr21:39705323..39705334,-#_2b468045fdc72e7b8a678e4811b22d2ep2@ENST00000436845
1.39e-27FFCP PHASE1:Hg19::chr21:39705323..39705334,-#_2b468045fdc72e7b8a678e4811b22d2ep2@ENST00000436845
2.46e-27FFCP PHASE1:Hg19::chr19:18895892..18895911,-#_406d46b7f8bbef35346a2deb3f5ed122p@chr19:18895892..18895911, -
2.46e-27FFCP PHASE2:Hg19::chr19:18895892..18895911,-#_406d46b7f8bbef35346a2deb3f5ed122p@chr19:18895892..18895911, -
3.11e-27FFCP PHASE2:Hg19::chr3:29966392..29966406,+#_c94ee2e3ee3a31b85f7356ed28151b0cp22@RBMS3
3.11e-27FFCP PHASE1:Hg19::chr3:29966392..29966406,+#_c94ee2e3ee3a31b85f7356ed28151b0cp22@RBMS3
3.89e-27FFCP PHASE2:Hg19::chr1:203151934..203151947,-#_e0cce13e7925b9ddfafaf932539c7ebap7@CHI3L1
3.89e-27FFCP PHASE1:Hg19::chr1:203151934..203151947,-#_e0cce13e7925b9ddfafaf932539c7ebap7@CHI3L1

Retrieved from "http://f5-webapp4.gsc.riken.jp/resource_browser/index.php?title=CL:0000135&oldid=3275204"